Results 131 to 140 of about 13,127,120 (318)
No time for complacency on the road to gender equality
The Lancet Global Health, 2020 The Lancet Global Health
doaj +1 more source
Molecular Oncology, EarlyView.Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
End-stage kidney disease in LMICs: rising to the challenge
The Lancet Global Health, 2017 The Lancet Global Health
doaj +1 more source
Now and then: lessons from the rollout of ART
The Lancet Global Health, 2021 The Lancet Global Health
doaj +1 more source
Metaphors of global health: jazz improvisation ensemble or classical orchestra?
, 2023 Reda Sadki
openalex +1 more source
3 Development of regional Networks by the NNEdPro global centre for nutrition & health [PDF]
, 2022 Cláudia Tramojntt +6 more
openalex +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Decolonising global health in 2021: a roadmap to move from rhetoric to reform
BMJ Global Health, 2021 M. Khan +5 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source